Lung Transplantation
Conditions
Interventions
iNO treatment group:Group A (Treatment Group): Patients will begin inhaling iNO at 10 ppm immediately after surgery in the ICU, continuing for 40 hours, followed by a gradual reduction in concentratio
Control Group):Group B (Control Group): Patients will receive standard ventilation protocols without inhaling iNO.
Sponsors
The Second Affiliated Hospital Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age =18 years Patients scheduled for lung transplantation Able to understand the purpose of the study and potential risks, and willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: Combined organ transplantation Non-first-time lung transplantation Preoperative ECMO bridging for lung transplantation Donor was a cardiac death Pregnancy Known allergy to prostaglandins (extremely rare) Need for or planned use of NO donor drugs (nitroglycerin, sodium nitroprusside, nicorandil, FK409, SIN-1, isosorbide mononitrate, and isosorbide dinitrate) Participant involvement in another conflicting clinical study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of PGD-2/3; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of PGD-2/3;Changes in pulmonary artery pressure;Inflammatory levels in bronchoalveolar lavage fluid;Duration of mechanical ventilation post-surgery;Duration of ECMO use;Duration of ICU stay and total hospitalization time;Incidence rate of acute kidney injury;mortality rates; | — |
Countries
China
Contacts
Public ContactMan Huang
The Second Affiliated Hospital Zhejiang University School of Medicine
Outcome results
None listed